Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smaller liver grafts could revolutionize transplant safety

NCT ID NCT07247877

Disease control Sponsor: Zhi-Jun Zhu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at a new way to do liver transplants for people with severe portal hypertension. Instead of using a full-sized liver, doctors will use a smaller piece (small-for-size graft) in an auxiliary transplant, leaving part of the original liver in place. The goal is to see if this method is safer and works as well as the standard transplant. About 396 participants will be followed to compare survival, complications, and whether the high blood pressure in the liver gets better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
auxiliary liver transplantation using small-for-size grafts
What this could lead to
If successful, this technique could offer a safer alternative to conventional liver transplantation for managing portal hypertension, potentially reducing complications.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. The technique is still being tested and may not be suitable for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 396 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2014

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with cirrhotic portal hypertension who were treated at the Liver Transplantation Center of Beijing Friendship Hospital, Capital Medical University between January 2014 and December 2028, and who underwent either auxiliary liver transplantation using small-for-size grafts (study group) or conventional liver transplantation (control group).

Ages

14 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \> 14 years. 2. Presence of decompensated portal hypertension. 3. Meeting the indications for liver transplantation surgery. 4. International Normalized Ratio (INR) \< 2.4. 5. Scheduled to undergo orthotopic auxiliary partial liver transplantation or conventional liver transplantation. Exclusion Criteria: 1. Rare liver-related anatomical variations. 2. Presence of contraindications to liver transplantation combined with malignant tumors. 3. Grade III or higher portal vein thrombosis. 4. Severe systemic diseases unrelated to the etiology or complications of portal hypertension. 5. Special surgical procedures such as dual-graft liver transplantation. 6. Special graft sources including domino liver transplantation. 7. Liver re-transplantation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver transplantation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver transplantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.